At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 360 enrolled
Drug / intervention
Tislelizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating Tislelizumab, Paclitaxel, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 360 participants across 43 sites.
Detailed Summary
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartJul 2018
Primary CompletionSep 2020
Study CompletionApr 2023
TodayJul 2026
First PostedJul 20, 2018
Enrollment StartJul 30, 2018
Primary CompletionSep 30, 2020
Study CompletionApr 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.0 years ago
Interventions
Tislelizumabdrug
Administered intravenously as described
Paclitaxeldrug
Administered intravenously as described
Nab-paclitaxeldrug
Administered intravenously as described
Carboplatindrug
Administered intravenously as described